Construction of the plant will commence in 2025 with first production expected to be in 2027
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
EDQM has also issued a Certificate of Suitability for Allopurino
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Subscribe To Our Newsletter & Stay Updated
